"CD40 Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Members of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. They are found on mature B-LYMPHOCYTES, some EPITHELIAL CELLS; and lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations in the CD40 antigen gene result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D019013
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.097 D23.050.301.264.051.140 D23.101.100.150.140
|
| Concept/Terms |
CD40 Antigens- CD40 Antigens
- TNFRSF5 Receptor
- Receptor, TNFRSF5
- CDw40 Antigen
- Antigen, CDw40
- Tumor Necrosis Factor Receptor Superfamily, Member 5
- CD40 Antigen
- Antigen, CD40
- Antigens, CD40
|
Below are MeSH descriptors whose meaning is more general than "CD40 Antigens".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- CD40 Antigens [D12.776.543.750.705.852.760.097]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- CD40 Antigens [D23.050.301.264.051.140]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- CD40 Antigens [D23.101.100.150.140]
Below are MeSH descriptors whose meaning is more specific than "CD40 Antigens".
This graph shows the total number of publications written about "CD40 Antigens" by people in this website by year, and whether "CD40 Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD40 Antigens" by people in Profiles.
-
Stein MN, Dumbrava EE, Teply BA, Gergis US, Guiterrez ME, Reshef R, Subudhi SK, Jacquemont CF, Senesac JH, Bayle JH, Scripture CD, Chatwal MS, Bilen MA, Stadler WM, Becerra CR. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
-
Khong A, Cleaver AL, Fahmi Alatas M, Wylie BC, Connor T, Fisher SA, Broomfield S, Lesterhuis WJ, Currie AJ, Lake RA, Robinson BW. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. BMC Cancer. 2014 Dec 17; 14:969.
-
Lucas CR, Cordero-Nieves HM, Erbe RS, McAlees JW, Bhatia S, Hodes RJ, Campbell KS, Sanders VM. Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes. J Immunol. 2013 Jan 15; 190(2):723-36.
-
Malon JT, Maddula S, Bell H, Cao L. Involvement of calcitonin gene-related peptide and CCL2 production in CD40-mediated behavioral hypersensitivity in a model of neuropathic pain. Neuron Glia Biol. 2011 May; 7(2-4):117-28.
-
Bamboat ZM, Ocuin LM, Balachandran VP, Obaid H, Plitas G, DeMatteo RP. Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretion. J Clin Invest. 2010 Feb; 120(2):559-69.
-
Worgall S, Martushova K, Busch A, Lande L, Crystal RG. Apoptosis induced by Pseudomonas aeruginosa in antigen presenting cells is diminished by genetic modification with CD40 ligand. Pediatr Res. 2002 Nov; 52(5):636-44.